Skip to content

Hero image: A young cancer patient meeting an oncologist and fertility specialist together

All insights

Specialist and Emerging Care

Fertility Preservation After a Cancer Diagnosis: Make Time for the Conversation

11 min readEvidence synthesis
Read the evidence

The question in focus

A current oncofertility guide to counseling, egg, embryo and ovarian-tissue cryopreservation, treatment timing, survivorship and equitable access.

Evidence at a glance

3 established cryopreservation options

embryo, oocyte and ovarian-tissue cryopreservation for appropriate patients

The 2025 ASCO update recognizes all three as established fertility-preservation approaches. Suitability depends on age, pubertal status, treatment urgency, cancer type, ovarian involvement and patient preference. [1]

Fertility Preservation in People With Cancer: ASCO Guideline Update

The discussion should happen before treatment whenever possible

Chemotherapy, pelvic radiation, ovarian or uterine surgery, stem-cell transplantation and some long-term endocrine treatments can affect ovarian function, the uterus or the timing of future pregnancy. ASCO recommends discussing reproductive risk and fertility preservation at diagnosis and revisiting it during survivorship. [1] The conversation should not depend on relationship status, parity, sexual orientation or an assumption about future parenthood.

Urgent cancer treatment remains the priority, but referral can occur in parallel with staging and treatment planning. A fertility specialist can often advise quickly whether preservation is feasible without clinically important delay. When treatment cannot wait, documenting the discussion and options considered remains important, and post-treatment reproductive assessment may still offer choices.

  • Ask about future genetic parenthood without making assumptions.
  • Refer promptly to an oncofertility service.
  • Coordinate timing with the oncology team.
  • Document when treatment urgency limits options.

Risk is determined by the treatment and the person

Gonadotoxic risk varies with drug class and cumulative dose, radiation field and dose, surgery, age, baseline ovarian reserve and underlying condition. A broad label such as chemotherapy is not enough. The oncology team should provide the proposed regimen, timing and likelihood of change so fertility counseling is grounded in the actual plan. [1][4]

Ovarian reserve tests can inform expected response to stimulation but cannot guarantee future fertility or precisely predict menopause. Treatment may also affect the uterus, pregnancy safety or recurrence considerations even when eggs remain. Counseling should cover ovarian function, ability to carry a pregnancy, genetic risk, treatment interruption and safe pregnancy timing as separate questions. [1][4]

  • Name the exact planned therapies and doses when known.
  • Assess ovarian and uterine exposure separately.
  • Do not use one ovarian-reserve result as a fertility forecast.
  • Reassess when the cancer plan changes.

Established options solve different constraints

Embryo and oocyte cryopreservation usually require controlled ovarian stimulation and an egg-retrieval procedure. Embryo freezing requires a sperm source, while oocyte freezing preserves reproductive autonomy over future fertilization. Outcomes depend strongly on age at freezing, number of mature oocytes or embryos and later laboratory and clinical factors. They should be discussed with individualized estimates rather than advertised success rates.

Ovarian-tissue cryopreservation does not require ovarian stimulation and can be performed quickly. ASCO recognizes it as established and notes that it may be the only preservation method available before puberty. [1] Future transplantation can restore ovarian function, but suitability depends on surgical risk and concern that tissue could contain malignant cells, particularly in some hematologic cancers.

  • Compare oocyte, embryo and tissue options directly.
  • Discuss whether more than one method is appropriate.
  • Include storage, future use and disposition decisions.
  • Explain age-specific uncertainty in future live birth.

Other strategies are adjuncts or diagnosis specific

Ovarian transposition may move ovaries away from a planned radiation field, but it does not protect against systemic chemotherapy and may complicate later egg retrieval. Fertility-sparing gynecologic surgery can be appropriate for selected early-stage cancers under specialist protocols. These choices require oncologic safety assessment and are not interchangeable with cryopreservation.

Gonadotropin-releasing hormone agonists during chemotherapy may be offered as an adjunct in selected patients, including some with breast cancer, but should not replace established preservation methods when those are feasible. [2] In-vitro maturation is described by ASCO as an emerging option for some patients. The label emerging should trigger a clear discussion of experience, evidence and alternatives.

  • Ask whether an option is established, adjunctive or emerging.
  • Do not let ovarian suppression replace referral automatically.
  • Confirm oncologic eligibility for fertility-sparing surgery.
  • Plan future surveillance and obstetric care.

Survivorship reopens the reproductive conversation

ASCO's update explicitly extends fertility-preservation counseling into survivorship. [3] Some people were too ill, too young or not referred before treatment. Others develop new goals later. Post-treatment assessment can address menstrual function, premature ovarian insufficiency, residual fertility, uterine health, sexual symptoms and whether preservation or assisted reproduction remains possible.

Timing of pregnancy after cancer depends on recurrence pattern, ongoing endocrine therapy, age and individual health. A return of periods does not prove normal fertility, and absent periods do not define every available family-building route. Decisions about pausing endocrine therapy or attempting pregnancy must be made with oncology and reproductive specialists using the relevant cancer evidence.

  • Revisit fertility goals during survivorship visits.
  • Assess ovarian function and uterine exposure after treatment.
  • Coordinate any treatment interruption with oncology.
  • Address menopause and sexual health alongside fertility.

Cost, coverage, geography, language, referral delay and storage fees can block access even when preservation is medically indicated. ASCO describes insurance gaps as a major barrier. [4] Programs should measure referral offer, consultation completion and preservation uptake without treating uptake as the only successful outcome. An informed decision to decline is valid.

Consent should cover procedure risks, chance of obtaining no usable material, storage duration and cost, future disposition, death or incapacity, legal parentage and limits on outcome prediction. For minors, developmentally appropriate assent and parent or guardian permission should protect future autonomy as far as possible. Ethical guidance emphasizes early information and all viable options. [5]

  • Offer navigation and financial counseling promptly.
  • Use trained interpreters for complex consent.
  • Plan long-term contact and disposition decisions.
  • Audit equitable referral across diagnoses and populations.

What the evidence cannot yet answer

  • Live-birth estimates depend on age, number of stored gametes or embryos, laboratory performance and future health.
  • Evidence for ovarian-tissue transplantation is growing, but cancer-specific safety and tissue-contamination risk vary.
  • Ovarian-reserve tests cannot precisely predict an individual's post-treatment fertility.
  • Emerging methods such as in-vitro maturation have less mature effectiveness evidence than standard cryopreservation.

Questions worth taking into care

  1. What fertility and pregnancy risks come from my exact cancer plan?
  2. Can a fertility consultation happen without delaying urgent treatment?
  3. Which options are established, adjunctive or emerging for me?
  4. What outcome estimates are specific to my age and expected response?
  5. Who will revisit fertility, menopause and sexual health in survivorship?

Source record

Evidence used in this review

Sources were selected for clinical authority, methodological relevance and traceability. Links open the original guidance, public-health record or research publication.

  1. [1]
    Fertility Preservation in People With Cancer: ASCO Guideline Update

    American Society of Clinical Oncology · 2025

  2. [2]
    Fertility Preservation in People With Cancer: Clinical Insights

    American Society of Clinical Oncology · 2025

  3. [3]
    ASCO Updates Clinical Practice Guidelines on Fertility Preservation

    American Society of Clinical Oncology · 2025

  4. [4]
  5. [5]
  6. [6]
Editorial standard

This evidence synthesis is for general information. It does not diagnose a condition or replace care from a qualified health professional. Treatment choices depend on individual history, examination, local guidance and informed preference. Emergency or rapidly worsening symptoms need urgent local medical assessment.